Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ocrevus
Pharma
Roche's Vabysmo will rise above Eylea biosim threat, exec says
While Vabysmo and Ocrevus are Roche's largest assets, the biggest surprise in the company's Q3 came from Elevidys, the DMD gene therapy from Sarepta.
Angus Liu
Oct 23, 2024 11:24am
Roche doubles down with subcutaneous FDA nod for MS star Ocrevus
Sep 13, 2024 1:50pm
Sales for Roche's Vabysmo rise again, but momentum is stalled
Jul 25, 2024 11:45am
Roche touts near-complete MS suppression for injectable Ocrevus
Apr 17, 2024 11:00am
Roche's subcutaneous Ocrevus stacks up to original IV version
Oct 11, 2023 7:22am
As Roche rival draws near, TG crashes on subpar MS drug sales
Aug 2, 2023 11:00am
